Related Experiment Video
Updated: Aug 18, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Development of antiviral therapy for severe acute respiratory syndrome
Jindrich Cinatl1, Martin Michaelis, Gerold Hoever
1Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. Cinatl@em.uni-frankfurt.de
Abstract:
A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.
Related Concept Videos
Respiratory Syncytial Virus Disease
Coronavirus
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Inhibitors Of Virion Release

